Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22790646 | 0.89 | KDM4E (0.47) | EPHX2FAAHLMNAKMT2AALDH1A1 | |
| SCHEMBL24508250 | 0.89 | KDM4E (0.47) | EPHX2FAAHLMNAKMT2AALDH1A1 | |
| SCHEMBL23696123 | 0.87 | KDM4E (0.48) | EPHX2FAAHLMNAKMT2AALDH1A1 | |
| SCHEMBL23559960 | 0.86 | KMT2A (0.50) | EPHX2FAAHLMNAKMT2AMEN1 | |
| SCHEMBL22790739 | 0.86 | FAAH (0.53) | EPHX2FAAHKMT2AMEN1TSHR | |
| SCHEMBL22906477 | 0.86 | FAAH (0.53) | EPHX2FAAHKMT2AMEN1TSHR | |
| SCHEMBL22837679 | 0.84 | EPHX2 (0.45) | EPHX2FAAHLMNAKMT2AMEN1 | |
| SCHEMBL21105769 | 0.84 | EPHX2 (0.45) | EPHX2FAAHLMNAKMT2AMEN1 | |
| SCHEMBL21107499 | 0.84 | EPHX2 (0.45) | EPHX2FAAHLMNAKMT2AMEN1 | |
| SCHEMBL21106554 | 0.84 | EPHX2 (0.45) | EPHX2FAAHLMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |